School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
    • Contact Us
  • Education
    • Degree and Certificate Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory

Directory section navigation

  • Faculty Profiles

Emory University School of Medicine

  • About
    • Sub link
      Our Vision
    • Sub link
      Academic Departments
    • Sub link
      Our Leadership
    • Sub link
      Health Care Partnerships
    • Sub link
      Diversity, Equity, & Inclusion
    • Sub link
      Location
    • Sub link
      Supporting Our People
    • Sub link
      Our Faculty
    • Sub link
      History
    • Sub link
      News
    • Sub link
      Events
    • Sub link
      Contact Us
  • Education
    • Sub link
      Degree and Certificate Programs
    • Sub link
      Academic Departments
    • Sub link
      Residents & Fellows
    • Sub link
      Postdoctoral Training
    • Sub link
      Continuing Medical Education
    • Sub link
      Admissions
    • Sub link
      Cost and Financial Aid
    • Sub link
      Student Resources
  • Research
    • Sub link
      Research Innovation
    • Sub link
      Conducting Research
    • Sub link
      Core Facilities
    • Sub link
      Research Centers
    • Sub link
      Research Training
    • Sub link
      Academic Departments
    • Sub link
      Find a Researcher
    • Sub link
      Research News
  • Clinical Experience
    • Sub link
      Where We Work
    • Sub link
      Caring for a Diverse Population
    • Sub link
      Faculty Clinical Experience
    • Sub link
      Advanced Patient Care
    • Sub link
      Academic Departments
    • Sub link
      Community Learning
  • Giving
  • Directory
  • Home School of Medicine Home
  • Directory

Profile

Kelly Goldsmith

  • Department of Pediatrics
    Professor
  • kgoldsm@emory.edu
  • Children's Healthcare of Atlanta
  • Aflac Cancer and Blood Disorders Center
    Pediatrics
    1760 Haygood Drive
Head shot of Kelly Goldsmith

Academic Appointment

  • Associate Professor of Pediatrics, Emory University

Education

Degrees

  • MD from University of Alabama School of Medicine
  • BS from Duke University

Research

Focus

  • My research focuses on the molecular mechanisms of chemoresistance in neuroblastoma (NB), a highly lethal pediatric solid tumor, and on the use of experimental therapeutics to restore therapy sensitivity through the re-engagement of programmed cell death.

Publications

  • Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia.
    Pediatr Blood Cancer Volume: 72 Page(s): e31714
    07/01/2025 Authors: Karol SE; Khaw SL; Zwaan CM; Baruchel A; Bittencourt H; Cooper TM; Flotho C; Fraser C; Forlenza CJ; Goldsmith KC
  • Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.
    J Clin Oncol Page(s): JCO2402612
    06/23/2025 Authors: Cash T; Marachelian A; DuBois SG; Chi Y-Y; Baregamyan A; Groshen SG; Jonus HC; Shamirian A; Crowley M; Goodarzian F
  • Protocol for 3D bioprinting of a 3D in vitro model of neuroblastoma.
    STAR Protoc Volume: 6 Page(s): 103725
    06/20/2025 Authors: Amoli MS; Rezapourdamanab S; Jin L; Cadena MA; Kaw K; Sridhar V; Meselhe M; Krikor S; Mahmoudi M; Ning L
  • Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum.
    Pediatr Blood Cancer Page(s): e31831
    06/12/2025 Authors: DuBois SG; Moreno L; Anderson J; Asgharzadeh S; Bagatell R; Beck-Popovic M; Belle J; Berlanga P; Bird NJ; Chesler L
  • Trends in analgesia-sedation of pediatric patients receiving I-131 MIBG in the pediatric intensive care unit: A report from the Pediatric Health Information System database.
    Pediatr Blood Cancer Volume: 71 Page(s): e31205
    10/01/2024 Authors: Dhuse J; Cash T; Elges MS; Alazraki A; Beer R; Jergel A; Goldsmith KC; Hall M; Kamat PP
  • Current and Emerging Biomarkers: Impact on Risk Stratification for Neuroblastoma.
    J Natl Compr Canc Netw Volume: 22
    08/01/2024 Authors: Irwin MS; Goldsmith KC
  • Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin.
    Commun Biol Volume: 7 Page(s): 426
    04/08/2024 Authors: Mittal K; Cooper GW; Lee BP; Su Y; Skinner KT; Shim J; Jonus HC; Kim WJ; Doshi M; Almanza D
  • Children's Oncology Group's 2023 blueprint for research: Neuroblastoma.
    Pediatr Blood Cancer Volume: 70 Suppl 6 Page(s): e30572
    09/01/2023 Authors: Bagatell R; DuBois SG; Naranjo A; Belle J; Goldsmith KC; Park JR; Irwin MS; COG Neuroblastoma Committee
  • A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.
    Volume: 70 Page(s): e30405
    08/01/2023 Authors: Cash T; Jonus HC; Tsvetkova M; Beumer JH; Sadanand A; Lee JY; Henry CJ; Aguilera D; Harvey RD; Goldsmith KC
  • Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma.
    Cell Rep Med Volume: 4 Page(s): 101091
    06/20/2023 Authors: Lee JY; Jonus HC; Sadanand A; Branella GM; Maximov V; Suttapitugsakul S; Schniederjan MJ; Shim J; Ho A; Parwani KK
  • Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
    Nat Commun Volume: 14 Page(s): 2601
    05/05/2023 Authors: Berko ER; Witek GM; Matkar S; Petrova ZO; Wu MA; Smith CM; Daniels A; Kalna J; Kennedy A; Gostuski I
  • Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
    Nat Med Volume: 29 Page(s): 1092 - 1102
    05/01/2023 Authors: Goldsmith KC; Park JR; Kayser K; Malvar J; Chi Y-Y; Groshen SG; Villablanca JG; Krytska K; Lai LM; Acharya PT
  • The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1.
    Oncoimmunology Volume: 12 Page(s): 2240678
    01/01/2023 Authors: Pilgrim AA; Jonus HC; Ho A; Cole AC; Shim J; Goldsmith KC
  • Identification of a Novel NRG1 Fusion with Targeted Therapeutic Implications in Locally Advanced Pediatric Cholangiocarcinoma: A Case Report.
    Case Rep Oncol Volume: 16 Page(s): 249 - 255
    01/01/2023 Authors: Mitchell SG; Basu GD; Eaton B; Goodman LJ; Goldsmith KC
  • VENETOCLAX IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY SOLID TUMORS: UPDATED FINDINGS FROM A PHASE 1 STUDY
    Volume: 69
    11/01/2022 Authors: Morgenstern D; Khaw S; Gerber N; Place A; Corradini N; Loh M; Verschuur A; Ziegler D; Fraser C; Cooper T
  • A 3D Bioprinted in vitro Model of Neuroblastoma Recapitulates Dynamic Tumor-Endothelial Cell Interactions Contributing to Solid Tumor Aggressive Behavior.
    Adv Sci (Weinh) Volume: 9 Page(s): e2200244
    08/01/2022 Authors: Ning L; Shim J; Tomov ML; Liu R; Mehta R; Mingee A; Hwang B; Jin L; Mantalaris A; Xu C
  • Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance.
    EMBO J Volume: 41 Page(s): e108272
    04/19/2022 Authors: oku J; Booth DM; Skoda J; Pedrotty MC; Vogel J; Liu K; Vu A; Carpenter EL; Ye JC; Chen MA
  • Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care.
    JCO Precis Oncol Volume: 6 Page(s): e2100451
    04/01/2022 Authors: Summers RJ; Castellino SM; Porter CC; MacDonald TJ; Basu GD; Szelinger S; Bhasin MK; Cash T; Carter AB; Castellino RC
  • Dissecting the cellular components of ex vivo T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials.
    Oncoimmunology Volume: 11 Page(s): 2057012
    01/01/2022 Authors: Jonus HC; Burnham RE; Ho A; Pilgrim AA; Shim J; Doering CB; Spencer HT; Goldsmith KC
  • Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
    J Clin Oncol Volume: 39 Page(s): 3506 - 3514
    11/01/2021 Authors: DuBois SG; Granger MM; Groshen S; Tsao-Wei D; Ji L; Shamirian A; Czarnecki S; Goodarzian F; Berkovich R; Shimada H
  • A New Player in Neuroblastoma: YAP and Its Role in the Neuroblastoma Microenvironment.
    Cancers (Basel) Volume: 13
    09/16/2021 Authors: Shim J; Goldsmith KC
  • High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells.
    Mol Cancer Ther Volume: 20 Page(s): 1161 - 1172
    06/01/2021 Authors: Vernooij L; Bate-Eya LT; Alles LK; Lee JY; Koopmans B; Jonus HC; Schubert NA; Schild L; Lelieveld D; Egan DA
  • COMPARISON OF OBSERVED LORLATINIB PHARMACOKINETICS IN SPECIAL POPULATIONS TO SIMULATIONS BASED ON THE PRIOR POPULATION PHARMACOKINETIC (POPPK) MODEL DEVELOPED USING DATA FROM ADULT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC).
    Volume: 109 Page(s): S55 - S55
    03/01/2021 Authors: Huynh D; Lin S; Mosse Y; Goldsmith K; Pithavala Y; Chen J
  • YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma.
    Cancer Res Volume: 80 Page(s): 4741 - 4753
    11/01/2020 Authors: Shim J; Lee JY; Jonus HC; Arnold A; Schnepp RW; Janssen KM; Maximov V; Goldsmith KC
  • NEXT-GENERATION SEQUENCING REVEALS INCREASED PREVALENCE OF PICALM-MLLT10 FUSIONS IN T-ALL AND T-LLY
    Volume: 67 Page(s): S167 - S167
    06/01/2020 Authors: Summers R; Aumann W; Pauly M; Goldsmith K; Porter C; Worsley R; Graham D; Castellino S; Wechsler D
  • Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium.
    Volume: 38
    05/20/2020 Authors: DuBois SG; Granger M; Groshen SG; Tsao-Wei D; Shamirian A; Czarnecki S; Goodarzian F; Berkovich R; Shimada H; Mosse YP
  • A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
    Volume: 67 Page(s): e28134
    04/01/2020 Authors: Qayed M; Cash T; Tighiouart M; MacDonald TJ; Goldsmith KC; Tanos R; Kean L; Watkins B; Suessmuth Y; Wetmore C
  • Multidisciplinary Care of Adult Wilms' Tumor During Pregnancy: A Case Report and Review of the Literature.
    Clin Genitourin Cancer Volume: 18 Page(s): e1 - e4
    02/01/2020 Authors: Brown JT; Harik LR; Barbee MS; Esiashvili N; Badell ML; Goldsmith KC; Master VA; Bilen MA
  • Mentors' perspectives on the successes and challenges of mentoring in the COG Young Investigator mentorship program: A report from the Children's Oncology Group.
    Pediatr Blood Cancer Volume: 66 Page(s): e27920
    10/01/2019 Authors: Esbenshade AJ; Kahalley LS; Baertschiger R; Dasgupta R; Goldsmith KC; Nathan PC; Harker-Murray P; Kitko CL; Kolb EA; Murphy ES
  • Predictive biomarkers for Bcl2-inhibitor use in neuroblastoma
    Volume: 79
    07/01/2019 Authors: Zapata C; Coku J; Liu K; Vu A; Goutnik M; Reynolds CP; Goldsmith K; Hogarty M
  • Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma.
    Nat Commun Volume: 10 Page(s): 2410
    06/03/2019 Authors: Maximov V; Chen Z; Wei Y; Robinson MH; Herting CJ; Shanmugam NS; Rudneva VA; Goldsmith KC; MacDonald TJ; Northcott PA
  • BCL2-INHIBITOR RESPONSE IN NEUROBLASTOMA: BIOMARKERS AND THERAPY RESISTANCE
    Volume: 66
    06/01/2019 Authors: Zapata C; Coku J; Liu K; Vu A; Goutnik M; Bodducherla R; Reynolds CP; Goldsmith K; Hogarty M
  • Ex vivo expanded patient-derived T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model.
    Oncoimmunology Volume: 8 Page(s): 1593804
    01/01/2019 Authors: Zoine JT; Knight KA; Fleischer LC; Sutton KS; Goldsmith KC; Doering CB; Spencer HT
  • Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.
    Clin Cancer Res Volume: 24 Page(s): 6142 - 6149
    12/15/2018 Authors: DuBois SG; Mosse YP; Fox E; Kudgus RA; Reid JM; McGovern R; Groshen S; Bagatell R; Maris JM; Twist CJ
  • The properties of ex vivo expanded gamma delta T cells provide for the rational use of combination therapies
    Volume: 78
    10/01/2018 Authors: Zoine JT; Sutton KS; Knight KA; Goldsmith KC; Doering CB; Spencer HT
  • Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.
    Future Oncol Volume: 14 Page(s): 2115 - 2129
    09/01/2018 Authors: Place AE; Goldsmith K; Bourquin J-P; Loh ML; Gore L; Morgenstern DA; Sanzgiri Y; Hoffman D; Zhou Y; Ross JA
  • TARGETING THE YES-ASSOCIATED PROTEIN IN NEUROBLASTOMA
    Volume: 65
    06/01/2018 Authors: Shim J; Janssen K; Arnold A; Lee YJ; Fritz A; Goldsmith K
  • Hyperleukocytosis in infant acute leukemia: a role for manual exchange transfusion for leukoreduction.
    Transfusion Volume: 58 Page(s): 1149 - 1156
    05/01/2018 Authors: Runco DV; Josephson CD; Raikar SS; Goldsmith KC; Lew G; Pauly M; Fasano RM
  • Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis.
    Clin Cancer Res Volume: 23 Page(s): 5374 - 5383
    09/15/2017 Authors: Marachelian A; Villablanca JG; Liu CW; Liu B; Goodarzian F; Lai HA; Shimada H; Tran HC; Parra JA; Gallego R
  • Concurrent myeloid sarcoma, atypical teratoid/rhabdoid tumor, and hypereosinophilia in an infant with a germline SMARCB1 mutation.
    Pediatr Blood Cancer Volume: 64
    09/01/2017 Authors: Metts JL; Park SI; Soares BP; Fong C; Biegel JA; Goldsmith KC
  • Engineering Ex Vivo Serum-Free Expanded (Y)delta T Cells for the Treatment of Neuroblastoma
    Volume: 25 Page(s): 278 - 279
    05/01/2017 Authors: Zoine JT; Sutton KS; Goldsmith KC; Dasgupta A; McCarty D; Doering CB; Spencer HT
  • Favorable Local Control From Consolidative Radiation Therapy in High-Risk Neuroblastoma Despite Gross Residual Disease, Positive Margins, or Nodal Involvement.
    Int J Radiat Oncol Biol Phys Volume: 97 Page(s): 806 - 812
    03/15/2017 Authors: Ferris MJ; Danish H; Switchenko JM; Deng C; George BA; Goldsmith KC; Wasilewski KJ; Cash WT; Khan MK; Eaton BR
  • Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
    Cancer Med Volume: 5 Page(s): 1416 - 1424
    07/01/2016 Authors: Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
  • Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
    BMC Cancer Volume: 16 Page(s): 97
    02/13/2016 Authors: Tanos R; Karmali D; Nalluri S; Goldsmith KC
  • EGFR signaling defines Mcl1 survival dependency in neuroblastoma.
    Cancer Biol Ther Volume: 16 Page(s): 276 - 286
    01/01/2015 Authors: Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
  • Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma.
    Cell Death Dis Volume: 5 Page(s): e1072
    02/20/2014 Authors: Laetsch TW; Liu X; Vu A; Sliozberg M; Vido M; Elci OU; Goldsmith KC; Hogarty MD
  • EGFR regulates Mcl-1 dependence in chemoresistant and acquired ABT-737-resistant high-risk neuroblastoma (HR NB).
    Volume: 73
    04/15/2013 Authors: Peirce SK; Nalluri S; Abdella H; Goldsmith K
  • COUP-TF1 is a novel biomarker of therapy response in high-risk neuroblastoma
    Volume: 73
    04/15/2013 Authors: Abdella H; Nalluri S; Peirce SK; Goldsmith KC
  • Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma.
    Cancer Res Volume: 72 Page(s): 2565 - 2577
    05/15/2012 Authors: Goldsmith KC; Gross M; Peirce S; Luyindula D; Liu X; Vu A; Sliozberg M; Guo R; Zhao H; Reynolds CP
  • A synthetic-lethal screen identifies novel Mc11 regulators in neuroblastorna
    CANCER RESEARCH Volume: 72
    04/15/2012 Authors: Laetsch T; Liu X; Sliozberg M; Vido M; Vu A; Goldsmith K; Hogarty MD
  • BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists.
    Cell Death Differ Volume: 17 Page(s): 872 - 882
    05/01/2010 Authors: Goldsmith KC; Lestini BJ; Gross M; Ip L; Bhumbla A; Zhang X; Zhao H; Liu X; Hogarty MD
  • Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.
    Cancer Biol Ther Volume: 8 Page(s): 1587 - 1595
    08/01/2009 Authors: Lestini BJ; Goldsmith KC; Fluchel MN; Liu X; Chen NL; Goyal B; Pawel BR; Hogarty MD
  • Small-molecule BH3 mimetics to antagonize Bcl-2-homolog survival functions in cancer.
    Curr Opin Investig Drugs Volume: 10 Page(s): 559 - 571
    06/01/2009 Authors: Goldsmith KC; Hogarty MD
  • RNA interference reveals heterogeneous pro-survival BH protein addiction and therapy resistance patterns in neuroblastoma
    CANCER RESEARCH Volume: 69
    05/01/2009 Authors: Lestini B; Goldsmith K; Chen N; Liu X; Hogarty M
  • The role of McI1 as a pro-survival protein in neuroblastoma
    PEDIATRIC BLOOD & CANCER Volume: 48 Page(s): 640 - 640
    06/01/2007 Authors: Fluchel MN; Lin A; Goldsmith KC; Liu X; Davis K; Bhumbla A; Ip L; London W; Hogarty MD
  • Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS).
    Blood Volume: 108 Page(s): 1965 - 1971
    09/15/2006 Authors: Teachey DT; Obzut DA; Axsom K; Choi JK; Goldsmith KC; Hall J; Hulitt J; Manno CS; Maris JM; Rhodin N
  • BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma.
    Oncogene Volume: 25 Page(s): 4525 - 4533
    08/03/2006 Authors: Goldsmith KC; Liu X; Dam V; Morgan BT; Shabbout M; Cnaan A; Letai A; Korsmeyer SJ; Hogarty MD
  • BH3-domain peptides synergize with cytotoxic agents to restore apoptosis sensitivity in chemoresistant neuroblastoma
    Volume: 66
    04/01/2006 Authors: Goldsmith K; Liu X; Goyal B; Lin A; Thambinayagan C; Davis K; Hogarty M
  • Single-stranded conformational polymorphism analysis improves radioactive detection of unequal X-inactivation - a case of childhood myelodysplastic syndrome.
    Volume: 7 Page(s): 691 - 691
    11/01/2005 Authors: Wildemore BM; Carlin A; Wang H; Goldsmith K; Kwiatkowski JL; Biegel J; Wilmoth D; Choi JK; Edmonston TB
  • Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma.
    Cancer Lett Volume: 228 Page(s): 133 - 141
    10/18/2005 Authors: Goldsmith KC; Hogarty MD
  • Rhabdomyosarcoma arising in a giant congenital melanocytic nevus.
    Cutis Volume: 73 Page(s): 39 - 43
    01/01/2004 Authors: Ilyas EN; Goldsmith K; Lintner R; Manders SM
Read more publications Fewer publications
Directory
  • Faculty Profiles
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2025 Emory University
  • Privacy Policy
  • Emergency Information
  • EEO Employer-Disability/Veteran Statements